Medias

Fatigue, poor recovery, the sense that energy has quietly slipped its moorings – menopause is often described in symptoms, yet experienced as something more diffuse, more systemic. Beneath it sits a shift in cellular metabolism; not abrupt, not singular, but cumulative. Mitochondria slow. Repair falters. The system, in small ways, begins to lose pace.

Elevant's focus on NMN (nicotinamide mononucleotide) places this experience within a different frame – one that looks beyond hormones alone and toward the bioenergetic architecture that supports them. The question becomes less about isolated symptoms and more about sustaining the machinery that produces energy in the first place; it's a subtle shift, but an important one.

Menopause is often sold to us as a simple hormonal equation: estrogen shifts, symptoms arrive. It's a convenient clinical frame, but it misses the deeper biological story. We're actually looking at a systemic transition – a point where mitochondrial function, inflammatory tone, and cellular energy metabolism all start to flag at the same time. This is where NAD⁺ enters the conversation. It's not just a molecule of the moment; it's the central operator of our energy and repair machinery. When those levels decline, the consequences aren't merely biochemical; they're deeply personal. Fatigue, a lack of resilience, the feeling of losing your recovery edge – this is energy as the felt expression of molecular aging.

If we change the angle, menopause ceases to be just a clinical hurdle to clear. It becomes a diagnostic window into the biology of aging itself, where the slow, diffuse processes of decline suddenly come into sharp, tangible focus. Supporting these pathways – through lifestyle, nutrition or targeted NAD⁺ precursors – represents a fundamental shift. We can start to move away from fighting symptoms one by one and towards supporting the system that gives rise to them. The ambition isn't to force the body into submission, but to partner with it, restoring balance where things have begun to slip, and in doing so, ensuring that we aren't just extending our years, but the vitality of the energy within them.

NAD⁺ and the biology of energy

At the cellular level, NAD⁺ is less a supporting actor than a central operator – a cofactor threading through oxidative phosphorylation, glycolysis and mitochondrial electron transport, quietly governing ATP production. It is also present elsewhere, where the stakes are different but no less significant – DNA repair via PARP enzymes, epigenetic regulation through sirtuins, the ongoing negotiation between damage and recovery.

With age, this system tightens. CD38 activity rises; PARP demand increases; the NAD⁺ salvage pathway loses efficiency. None of this happens dramatically. It accrues. The outcome is familiar – reduced energy, slower recovery, a narrowing of physiological margin.

In menopause, these dynamics sharpen. Reduced estrogen signalling intersects with mitochondrial regulation; oxidative stress increases; inflammatory tone shifts. The result is not one pathway failing, but several moving in the same direction – a convergence that is felt, quite simply, as fatigue.

Why NMN enters the frame

Within this context, NMN is positioned not as a general supplement, but as a pathway-specific intervention. As a direct precursor in NAD⁺ biosynthesis, it bypasses the rate-limiting NAMPT step and feeds more directly into intracellular NAD⁺ production. One fewer step. Slightly more efficient.

Elevant's approach builds on this logic, aiming to support NAD⁺ regeneration at the cellular level rather than relying on transient increases in circulating metabolites. The distinction is technical, but meaningful – where the intervention enters the system often determines what it can influence.

Preclinical work associated with Seneque, including research led by Alessia Grozio, has begun to map this pathway in greater detail, identifying mechanisms of NMN transport such as Slc12a8 and exploring its role in maintaining NAD⁺ homeostasis within aging systems [1,2]. Mechanism matters. Here, it is increasingly defined.

Clinical signals from NMN studies

Human data are beginning to follow. Clinical trials linked to Seneque – including NCT04910061 and NCT04862338 – have examined safety, tolerability and the impact of NMN supplementation on NAD⁺ levels [3,4]. Early findings suggest that NMN can increase circulating NAD⁺ metabolites, with a safety profile that appears acceptable in short-term use.

Beyond biomarkers, a second layer of inquiry is emerging – one that looks at function. Studies, including work published in Nutrients, have explored effects on fatigue, sleep and physical performance, while additional trials such as NCT04664361 investigate muscle recovery and exercise capacity [5,6]. Early, certainly. But directionally consistent.

The gap between molecule and experience begins to narrow.

From molecule to experience

For those navigating menopause, the translation is straightforward. Energy is not abstract; it is daily, practical, occasionally elusive. It is the difference between maintaining momentum and losing it.

Elevant's positioning of NMN sits within this translation – connecting molecular pathways to lived experience, and doing so in a way that reflects a broader shift within longevity science. Less focus on single symptoms; more attention to systems. Less fragmentation; more integration.

A broader shift in perspective

Menopause, seen through this lens, becomes something slightly different – not a discrete event, but a visible inflection point within a longer trajectory of metabolic change. An early signal. A useful one.

Support the system, and the rest may follow.

References

[1] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6530925/
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5668137/
[3] https://clinicaltrials.gov/ct2/show/NCT04910061
[4] https://clinicaltrials.gov/ct2/show/NCT04862338
[5] https://www.mdpi.com/2072-6643/14/4/755
[6] https://clinicaltrials.gov/ct2/show/NCT04664361

Source : Longevity.Technology